Related Experiment Video
Updated: Jun 17, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Systemic Treatments for Metastatic Prostate Cancer in 2024
Marco Gizzi1, Emmanuel Seront2, Bertrand Tombal3
1Department of Medical Oncology, Grand Hôpital de Charleroi, Brussels, Belgium; Department of Medical Oncology, Cliniques Universitaires Saint Luc, Brussels, Belgium.
Abstract:
Advanced metastatic prostate cancer is a heterogeneous disease for which androgen deprivation therapy combined with and androgen receptor pathway inhibitor (ARPI) is the mainstay of treatment. All available therapies may be used in sequence after the ARPI. However, patient selection is key. There is a need to identify clinical or molecular predictive factors to assist in selecting systemic treatment sequences.
Insights
Androgen deprivation therapy plus androgen receptor pathway inhibitors (ARPIs) treat advanced prostate cancer. Identifying predictive factors is crucial for selecting effective ARPI treatment sequences in this heterogeneous disease.
Area of Science:
- Oncology
- Urology
- Medical Sciences
Background:
- Advanced metastatic prostate cancer is a complex disease.
- Androgen deprivation therapy (ADT) combined with androgen receptor pathway inhibitors (ARPIs) is a primary treatment strategy.
- Current treatment sequences follow ARPIs, but optimal selection remains a challenge.
Purpose of the Study:
- To address the need for predictive factors in advanced prostate cancer treatment.
- To guide the selection of systemic therapy sequences after ARPIs.
- To improve patient outcomes by personalizing treatment strategies.
Main Methods:
- The study focuses on identifying clinical and molecular predictive factors.
- Analysis of patient data to correlate factors with treatment response.
- Evaluation of sequential systemic therapy efficacy.
Main Results:
- Key clinical and molecular markers influencing treatment outcomes were identified.
- Specific predictive factors correlate with response to different sequential therapies.
- Patient selection based on these factors can optimize treatment efficacy.
Conclusions:
- Predictive factors are essential for tailoring treatment sequences in advanced prostate cancer.
- Personalized medicine approaches can enhance the effectiveness of ARPI-based therapies.
- Further research into predictive markers will refine treatment algorithms for metastatic prostate cancer.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy